Randomization target of 200 patients completed ahead of schedule in the ARGO PsA trial Top-line 12-week results of the ARGO trial in PsA for the novel IL-17A and IL-17F inhibiting Nanobody ® ...

ZUG, Switzerland, February 2, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory ...

Covariate-adaptive randomization represents an advanced methodology in the design of clinical trials, ensuring a balanced distribution of prognostic factors among treatment groups. This approach ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead ...

Randomization Techniques (60 minutes): In this workshop, the rationale behind randomized experiments will be explained. Descriptions of commonly utilized randomization algorithms will be presented, ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...

ZUG, Switzerland, July 25, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, ...